Thalidomide
You would like to know more about the topic of Thalidomide? Then make use of this link
History
The Development – Grünenthal Group
2014 | Launch of Recivit® in the Netherlands, Denmark, UK and France. |
2014 | Versatis® is registered in 28 countries in the EU und worldwide in 48 countries. |
2013 | Grünenthal acquires Laboratorios Andrómaco S.A. and expands its business in the Andean countries and Central America. |
2013 | Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®®. |
2013 | Extension of product range in Latin America - Grünenthal takes over a portfolio of 30 products of BIOGEN® LABORATORIO, Colombia. |
2012 | Palexia® is available in UK, Spain, Italy, Denmark, Sweden, Ireland, Portugal, Norway, Belgium and Switzerland. |
2011 | FDA approval and launch of Tapentadol ER for chronic pain. |
2011 | Market introduction in the United States of INTAC®, an innovative formulation technology for the protection of intended drug action. |
2011 | Expansion of the Latin America business through founding of Grünenthal do Brasil Farmacêutica Ltda. |
2011 | Sale of business in Eastern Europe and the Middle East to the STADA Group. |
2011 | Sale of European Gynaecology Business to the Gedeon Richter Group. |
2010 | Marketing authorization of Tapentadol IR and PR in 26 EU countries |
2010 | Sale of the European Business on Cystic fibrosis (CF) to Forest Healthcare B.V. |
2009 | EU submission of Tapentadol for acute and chronic pain, launch of Nucynta® in the US by Johnson & Johnson |
2008 | Approval of Tapentadol in the US |
2007 | Versatis® obtains approval in EU (UK), followed by first European launch in the UK. |
since 2004 | Broad investments in R&D and late clinical trials |
since 2000 | Global launches (Zaldiar®, Transtec®) |
Since 1990 | Increasing internationalization of Grünenthal through local founding of subsidiaries and acquisitions |
1979 | Expansion of the Latin America business through founding of subsidiaries in Columbia and Chile |
1977 | Tramal® launched – worldwide partnering |
1968 | First international activities |
1957 | Launch of Thalidomide (withdrawn from market in 1961) |
1947 | Registration of Penicillin |
1946 | Hermann Wirtz founded Chemie Grünenthal GmbH |